Sanofi (SNY)
(Delayed Data from NSDQ)
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.
BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Novo Nordisk (NVO) Faces Pricing Pressure and Competition
by Zacks Equity Research
Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.
Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
by Zacks Equity Research
Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.
Emergent Completes Acquisition of Narcan Maker Adapt Pharma
by Zacks Equity Research
Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
by Zacks Equity Research
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
by Zacks Equity Research
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Here's Why Alynlam Pharmaceuticals is Hogging the Limelight
by Zacks Equity Research
Alnylam (ALNY) files an NDA for Onpattro in Japan and releases positive interim results for givosiran.
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer
by Zacks Equity Research
Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks
by Zacks Equity Research
Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa.
Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion
by Zacks Equity Research
Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.
Should Value Investors Consider Sanofi (SNY) Stock Now?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success
by Zacks Equity Research
Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
Is Artificial Intelligence the Next Big Thing in Biotech?
by Kinjel Shah
Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.